cilostazol has been researched along with Chronic Disease in 23 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this prospective, double-blind, randomized, placebo-controlled study was to evaluate the efficacy of cilostazol, a selective phosphodiesterase 3 inhibitor, in patients with chronic tinnitus." | 9.22 | Effect of a 4-Week Treatment with Cilostazol in Patients with Chronic Tinnitus: A Randomized, Prospective, Placebo-controlled, Double-blind, Pilot Study. ( Baek, S; Chung, JW; Kang, WS; Kim, TS; Lim, HW; Song, CI, 2016) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 8.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated." | 7.96 | Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia. ( Liu, Y; Ma, XY; Mang, J; Shao, MY; Sun, Y; Wang, LM; Wei, AX; Xu, ZX, 2020) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 7.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on cerebral circulation in chronic cerebral infarction was studied by the 133Xenon inhalation method." | 7.67 | Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. ( Katsube, T; Kitani, M; Kobayashi, S; Okada, K; Tsunematsu, T; Yamaguchi, S, 1985) |
| "OBJECTIVE Chronic hydrocephalus develops in association with the induction of tenascin-C (TNC), a matricellular protein, after aneurysmal subarachnoid hemorrhage (SAH)." | 5.46 | Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage. ( Kawakita, F; Nakatsuka, Y; Sakaida, H; Suzuki, H; Toma, N; Umeda, Y; Yasuda, R, 2017) |
| "Pretreatment with cilostazol significantly attenuated the increased migration of monocytes, possibly through suppression of platelet-monocyte interactions." | 5.35 | Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. ( Higashiyama, M; Hokari, R; Kawaguchi, A; Komoto, S; Kurihara, C; Matsunaga, H; Miura, S; Nagao, S; Nakamura, M; Okada, Y; Watanabe, C, 2009) |
| "The aim of this prospective, double-blind, randomized, placebo-controlled study was to evaluate the efficacy of cilostazol, a selective phosphodiesterase 3 inhibitor, in patients with chronic tinnitus." | 5.22 | Effect of a 4-Week Treatment with Cilostazol in Patients with Chronic Tinnitus: A Randomized, Prospective, Placebo-controlled, Double-blind, Pilot Study. ( Baek, S; Chung, JW; Kang, WS; Kim, TS; Lim, HW; Song, CI, 2016) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 4.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated." | 3.96 | Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia. ( Liu, Y; Ma, XY; Mang, J; Shao, MY; Sun, Y; Wang, LM; Wei, AX; Xu, ZX, 2020) |
| " We performed cognitive behavioral tests, including the water maze task, odor discrimination task, and novel object test; histological investigation of neuroinflammation, oligodendrocytes, myelin basic protein, and nodal or paranodal proteins at the nodes of Ranvier; and serial diffusion tensor imaging." | 3.83 | Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion. ( Back, DB; Choi, BR; Choi, DH; Han, JS; Han, SH; Kang, CH; Kim, BR; Kim, DH; Kim, HY; Kwon, KJ; Lee, J; Moon, WJ; Shin, CY, 2016) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 3.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "In order to find out the difference between cilostazol and ticlopidine hydrochloride in the cerebral vasodilating effect in the chronic stage of cerebral infarction, cerebral blood flows were measured while the patients were on ticlopidine hydrochloride and after ticlopidine hydrochloride was switched to cilostazol." | 3.70 | Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation. ( Mochizuki, Y; Oishi, M; Satoh, Y; Shikata, E, 2000) |
| "The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on cerebral circulation in chronic cerebral infarction was studied by the 133Xenon inhalation method." | 3.67 | Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. ( Katsube, T; Kitani, M; Kobayashi, S; Okada, K; Tsunematsu, T; Yamaguchi, S, 1985) |
| "Cilostazol was orally administered for 209 days on average." | 2.69 | [Effects of long-term administration of cilostazol on chronic cerebral circulatory insufficiency--with special reference to cerebral blood flow and clinical symptoms]. ( Anegawa, S; Furukawa, Y; Hayashi, T; Katsuragi, M; Tomokiyo, M; Torigoe, R, 1998) |
| "OBJECTIVE Chronic hydrocephalus develops in association with the induction of tenascin-C (TNC), a matricellular protein, after aneurysmal subarachnoid hemorrhage (SAH)." | 1.46 | Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage. ( Kawakita, F; Nakatsuka, Y; Sakaida, H; Suzuki, H; Toma, N; Umeda, Y; Yasuda, R, 2017) |
| "Cilostazol was administered for 6 days orally 1 day after compression treatment group (n = 6); the nontreatment group (n = 6) did not receive any drug." | 1.35 | The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model. ( Aoki, Y; Kikuchi, S; Konno, S; Sekiguchi, M, 2008) |
| "Cilostazol is a potent type III phosphodiesterase inhibitor, approved as an anti-platelet aggregation agent." | 1.35 | Activation of tyrosine hydroxylase prevents pneumonia in a rat chronic cerebral hypoperfusion model. ( Hattori, N; Miyamoto, N; Mochizuki, H; Tanaka, R; Urabe, T; Zhang, N, 2009) |
| "Pretreatment with cilostazol significantly attenuated the increased migration of monocytes, possibly through suppression of platelet-monocyte interactions." | 1.35 | Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. ( Higashiyama, M; Hokari, R; Kawaguchi, A; Komoto, S; Kurihara, C; Matsunaga, H; Miura, S; Nagao, S; Nakamura, M; Okada, Y; Watanabe, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, AX | 1 |
| Shao, MY | 1 |
| Liu, Y | 1 |
| Sun, Y | 1 |
| Wang, LM | 1 |
| Ma, XY | 1 |
| Mang, J | 1 |
| Xu, ZX | 1 |
| Shimatani, K | 1 |
| Sato, H | 1 |
| Saito, A | 1 |
| Sasai, M | 1 |
| Watanabe, K | 1 |
| Mizukami, K | 1 |
| Kamohara, M | 1 |
| Miyagawa, S | 1 |
| Sawa, Y | 1 |
| Wada, T | 1 |
| Onogi, Y | 1 |
| Kimura, Y | 1 |
| Nakano, T | 1 |
| Fusanobori, H | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Shi, L | 1 |
| Pu, J | 1 |
| Xu, L | 1 |
| Malaguit, J | 1 |
| Zhang, J | 1 |
| Chen, S | 1 |
| Choi, BR | 1 |
| Kim, DH | 1 |
| Back, DB | 1 |
| Kang, CH | 1 |
| Moon, WJ | 1 |
| Han, JS | 1 |
| Choi, DH | 1 |
| Kwon, KJ | 1 |
| Shin, CY | 1 |
| Kim, BR | 1 |
| Lee, J | 1 |
| Han, SH | 1 |
| Kim, HY | 1 |
| Nakatsuka, Y | 1 |
| Kawakita, F | 1 |
| Yasuda, R | 1 |
| Umeda, Y | 1 |
| Toma, N | 1 |
| Sakaida, H | 1 |
| Suzuki, H | 1 |
| Lim, HW | 1 |
| Kim, TS | 1 |
| Kang, WS | 1 |
| Song, CI | 1 |
| Baek, S | 1 |
| Chung, JW | 1 |
| Sekiguchi, M | 1 |
| Aoki, Y | 1 |
| Konno, S | 1 |
| Kikuchi, S | 1 |
| Zhang, N | 3 |
| Miyamoto, N | 2 |
| Tanaka, R | 3 |
| Mochizuki, H | 2 |
| Hattori, N | 2 |
| Urabe, T | 3 |
| Shimura, H | 1 |
| Onodera, M | 1 |
| Matsunaga, H | 1 |
| Hokari, R | 1 |
| Higashiyama, M | 1 |
| Kurihara, C | 1 |
| Okada, Y | 1 |
| Watanabe, C | 1 |
| Komoto, S | 1 |
| Nakamura, M | 1 |
| Kawaguchi, A | 1 |
| Nagao, S | 1 |
| Miura, S | 1 |
| Woo, JS | 1 |
| Kim, W | 1 |
| Lee, SR | 1 |
| Jung, KH | 1 |
| Kim, WS | 1 |
| Lew, JH | 1 |
| Lee, TW | 1 |
| Lim, CK | 1 |
| Bertelli, L | 1 |
| Amato, A | 1 |
| Sangiorgi, GM | 1 |
| Miller, MS | 1 |
| Zolli, A | 1 |
| Jelnes, R | 1 |
| Watanabe, T | 1 |
| Liu, M | 1 |
| Mizuno, Y | 1 |
| Shinohara, Y | 1 |
| Lee, JH | 1 |
| Park, SY | 1 |
| Shin, HK | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Torigoe, R | 1 |
| Hayashi, T | 1 |
| Anegawa, S | 1 |
| Furukawa, Y | 1 |
| Tomokiyo, M | 1 |
| Katsuragi, M | 1 |
| Oishi, M | 1 |
| Mochizuki, Y | 1 |
| Shikata, E | 1 |
| Satoh, Y | 1 |
| Kobayashi, S | 1 |
| Yamaguchi, S | 1 |
| Katsube, T | 1 |
| Kitani, M | 1 |
| Okada, K | 1 |
| Tsunematsu, T | 1 |
| Kamiya, T | 1 |
| Sakaguchi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for cilostazol and Chronic Disease
| Article | Year |
|---|---|
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Topics: Acute Disease; Asian People; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Chronic Disease; Cil | 2014 |
Foot ulceration due to arterial insufficiency: role of cilostazol.
Topics: Aged; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Chronic Disease; Cilostazol | 2004 |
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
Topics: Cerebrovascular Disorders; Chronic Disease; Cilostazol; Clinical Trials as Topic; Humans; Ischemic A | 2008 |
3 trials available for cilostazol and Chronic Disease
17 other studies available for cilostazol and Chronic Disease
| Article | Year |
|---|---|
Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia.
Topics: Animals; Brain Ischemia; Cerebral Cortex; Chronic Disease; Cilostazol; Cyclin D1; Disease Models, An | 2020 |
A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates.
Topics: Angiogenesis Inducing Agents; Animals; Blood Flow Velocity; Cells, Cultured; Chronic Disease; Cilost | 2021 |
Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cilostazol; Diabetes Mellitus, E | 2013 |
Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion.
Topics: Animals; Behavior, Animal; Brain Ischemia; Carotid Stenosis; Chronic Disease; Cilostazol; Cognition; | 2016 |
Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage.
Topics: Aged; Chronic Disease; Cilostazol; Female; Humans; Hydrocephalus; Male; Middle Aged; Phosphodiestera | 2017 |
The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model.
Topics: Action Potentials; Acute Disease; Animals; Blood Flow Velocity; Cauda Equina; Chronic Disease; Cilos | 2008 |
Activation of tyrosine hydroxylase prevents pneumonia in a rat chronic cerebral hypoperfusion model.
Topics: Animals; Bacteria; Carotid Stenosis; Chronic Disease; Cilostazol; Corpus Striatum; Cyclic AMP Respon | 2009 |
Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Brain Ischemia; Carotid Stenosis; Cerebral Ventricles; Cerebrovascular Circulati | 2009 |
Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes.
Topics: Animals; Anti-Inflammatory Agents; Blood Platelets; Cell Movement; Chronic Disease; Cilostazol; Cycl | 2009 |
Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?
Topics: Aged; Atherosclerosis; Catheters; Chronic Disease; Cilostazol; Coronary Artery Bypass; Coronary Arte | 2012 |
Pharmacotherapy as adjunctive treatment for serious foot wounds in the patient with diabetes: a case study.
Topics: Administration, Topical; Anti-Bacterial Agents; Chronic Disease; Cilostazol; Combined Modality Thera | 2003 |
How reliable is preliminary evidence?
Topics: Arterial Occlusive Diseases; Chronic Disease; Cilostazol; Humans; Platelet Aggregation Inhibitors; R | 2004 |
Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Chronic Disease; Cilostazol; Cyclic AMP Response Element- | 2006 |
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Chronic Disease; Cilostazol; Female; Follow-Up Studies; H | 2006 |
Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation.
Topics: Aged; Carotid Arteries; Cerebral Infarction; Cerebrovascular Circulation; Chronic Disease; Cilostazo | 2000 |
Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction.
Topics: Aged; Azoles; Cerebral Infarction; Cerebrovascular Circulation; Chronic Disease; Cilostazol; Female; | 1985 |
Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities.
Topics: Aged; Ankle; Arterial Occlusive Diseases; Azoles; Chronic Disease; Cilostazol; Fibrinolytic Agents; | 1985 |